ORIGINAL ARTICLE |
|
Year : 2019 | Volume
: 5
| Issue : 1 | Page : 26-29 |
|
Oral ranitidine: A promising novel therapeutic option in molluscum contagiosum in children
Pooja Agarwal1, Bhushan Madke2, Priyanka Bodar1
1 Department of Skin and VD, Smt SCL General Hospital, Ahmedabad, Gujarat, India 2 Department of Skin and VD, Jawaharlal Nehru Medical College, AVBR Hospital, Wardha, Maharastra, India
Correspondence Address:
Dr. Bhushan Madke Department of Skin and VD, Jawaharlal Nehru Medical College, AVBR Hospital, Sawangi, Wardha, Maharastra India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijdd.ijdd_41_18
|
|
Background: Molluscum contagiosum(MC) is one of the most common cutaneous viral infection observed in children. Though, it is benign and self-limiting, treatment is often sought for cosmetic reasons. Existing invasive therapeutic modalities are generally not well tolerated in children because of pain and risk of scarring. Immunomodulatory potential of cimetidine is well established. We thus extrapolated the same to ranitidine and conducted this study. Aim: To assess the efficacy of oral ranitidine in treatment of molluscum contagiosum in immunocompetent children. Methods: A multicentre longitudinal study was conducted in the dermatology departments of tertiary care hospitals in Ahmedabad and Wardha, India over a period of 4 months. 24 children with MC were included. Oral ranitidine was started in dose of 5 mg/kg/day in two divided doses for 8 weeks. Follow up was done very 15 days and changes in number and size of lesions were noted. Results: Mean age of patients was 5.08 years. 19 patients completed the study. 15 patients had improvement in the lesions at the end of 8 weeks while 4 patients did not show any improvement. Complete clearance was seen in 14 patients(73.6%) and 1 patient had decrease in size of the lesions without change in the number. Mean duration of complete clearance of lesion was 6.5 weeks. Conclusion: Oral ranitidine may be considered as a safe and effective alternative therapeutic option in widespread MC in immunocompetent children where invasive painful procedures are less desirable.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|